ARRIVENT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ARRIVENT BIOPHARMA, INC. (AVBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $17.44 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $16.98, a 22.96% decline year-over-year.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $22.04, a 265.51% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $6.03, a 116.13% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $2.79.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $20.47, a 172.21% increase from fiscal 2024.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $7.52, a 110.64% increase from fiscal 2023.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $3.57.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.44 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $16.98 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $20.47 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $20.98 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $21.31 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | $22.04 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | $7.52 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $8.53 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $7.49 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | $6.03 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $3.57 10-K · filed 2025-03-03 | |||
| 2023-09-30 | $3.50 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $2.74 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | $2.79 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |